Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice

Journal of Virology

Volumn 81, Issue 16, 2007, Pages 8774-8783

  Perera, Liyanage P ^a   Waldmann, Thomas A ^a   Mosca, Joseph D ^b   Baldwin, Nicole ^c   Berzofsky, Jay A ^a   Oh, Sang Kon ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JDM Technologies Inc   (United States)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; MODIFIED VACCINIA VIRUS ANKARA VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BIOLOGICAL WARFARE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOSTIMULATION; LETHALITY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SMALLPOX; SMALLPOX VIRUS; SURVIVAL; VACCINATION; VIRUS STRAIN; VIRUS VIRULENCE; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; INTERLEUKIN-15; MICE; MICE, INBRED BALB C; SMALLPOX; SMALLPOX VACCINE; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

MUS; MUS MUSCULUS; VACCINIA VIRUS; VACCINIA VIRUS ANKARA; VARIOLA VIRUS;

EID: 34547818090     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00538-07     Document Type: Article

References (46)

1. Alexander, W. A., B. Moss, and T. R. Fuerst. 1992. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J. Virol. 66:2934-2942.
2. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 24:365-396.
3. Armitage, R. J., B. M. Macduff, J. Eisenman, R. Paxton, and K. H. Grabstein. 1995. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol. 154:483-490.
4. Belyakov. I. M., P. L. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100: 9458-9463.
5. Bernasconi, N. L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199-2202.
6. Centers for Disease Control and Prevention. 2003. Cardiac adverse events following smallpox vaccination - United States, 2003. Morb. Mortal. Wkly. Rep. 52:248-250.
7. Centers for Disease Control and Prevention. 2001. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Morb. Mortal. Wkly. Rep. 50(RR-10):1-25.
8. Cohen, J. 2001. Smallpox vaccinations: how much protection remains? Science 294:985.
9. Coulibaly, S., P. Bruhl, J. Mayrhofer, K. Schmid, M. Gerencer, and F. G. Falkner. 2005. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341:91-101.
10. Crotty, S., P. Feigner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171:4969-4973.
11. Demkowicz, W. E., Jr., R. A. Littaua, J. Wang, and F. A. Ennis. 1996. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol. 70:2627-2631.
12. Earl, P. L., J. L. Americo, L. S. Wyatt, L. A. Eller, J. C. Whitbeck, G. H. Cohen, R. J. Eisenberg, C. J. Hartmann, D. L. Jackson, D. A. Kulesh, M. J. Martinez, D. M. Miller, E. M. Mucker, J. D. Shamblin, S. H. Zwiers, J. W. Huggins, P. B. Jahrling, and B. Moss. 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182-185.
13. Edghill-Smith, Y., H. Golding, J. Manischewitz, L. R. King, D. Scott, M. Bray, A. Nalca, J. W. Hooper, C. A. Whitehouse, J. E. Schmitz, K. A. Reimann, and G. Franchini. 2005. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11:740-747.
14. Eichner, M. 2003. Analysis of historical data suggests long-lasting protective effects of smallpox vaccination. Am. J. Epidemiol. 158:717-723.
15. el-Ad, B., Y. Roth, A. Winder, Z. Tochner, T. Lublin-Tennenbaum, E. Katz, and T. Schwartz. 1990. The persistence of neutralizing antibodies after revaccination against smallpox. J. Infect. Dis. 161:445-448.
16. Empig, C., J. R. Kenner, M. Perret-Gentil, B. E. Youree, E. Bell, A. Chen, M. Gurwith, K. Higgins, M. Lock, A. D. Rice, J. Schriewer, F. Sinangil, E. White, R. M. Buller, T. S. Dermody, S. N. Isaacs, and R. W. Moyer. 2006. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 24:3686-3694.
17. Fauci, A. S. 2002. Smallpox vaccination policy - the need for dialogue. N. Engl. J. Med. 346:1319.
18. Fenner. F., D. A. Henderson, I. Arita, et al. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
19. Fogg, C., S. Lustig, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and B. Moss. 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78:10230-10237.
20. Halsell, J. S., J. R. Riddle, J. E. Atwood, the Department of Defense Smallpox Vaccination Clinical Evaluation Team, et al. 2003. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 289:3283-3289.
21. Hammarlund, E., M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M. Hanifin, and M. K. Slifka. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9:1131-1137.
22. Heraud, J. M., Y. Edghill-Smith, V. Ayala, I. Kalisz, J. Parrino, V. S. Kalyanaraman, J. Manischewitz, L. R. King, A. Hryniewicz, C. J. Trindade, M. Hassett, W. P. Tsai, D. Venzon, A. Nalca, M. Vaccari, P. Silvera, M. Bray, B. S. Graham, H. Golding, J. W. Hooper, and G. Franchini. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177:2552- 2564.
23. Herrero-Martinez, E., K. L. Roberts, M. Hollinshead, and G. L. Smith. 2005. Vaccinia virus intracellular enveloped virions move to the cell periphery on microtubules in the absence of the A36R protein. J. Gen. Virol. 86:2961-2968.
24. Hiroi, T., M. Yanagita, N. Ohta, G. Sakaue, and H. Kiyono. 2000. IL-15 and IL-15 receptor selectively regulate differentiation of common mucosal immune system-independent B-1 cells for IgA responses. J. Immunol. 165: 4329-4337.
25. Hooper, J. W., E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433-4443.
26. Hopkins, D. R. 1983. Princes and peasants: smallpox history. University of Chicago Press, Chicago, IL.
27. Kempe, C. H., C. Bowles, and T. Meiklejohn. 1961. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull. W. H. O. 25:41-48.
28. Kutzler, M. A., T. M. Robinson, M. A. Chattergoon, D. K. Choo, A. Y. Choo, P. Y. Choe, M. P. Ramanathan, R. Parkinson, S. Kudchodkar, Y. Tamura, M. Sidhu, V. Roopchand, J. J. Kim, G. N. Pavlakis, B. K. Felber, T. A. Waldmann, J. D. Boyer, and D. B. Weiner. 2005. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J. Immunol. 175:112-123.
29. Lane, J. M., F. L. Ruben, J. M. Neff, and J. D. Millar. 1970. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122:303-309.
30. Lane, J. M., F. L. Ruben, J. M. Neff, and J. D. Millar. 1969. Complications of a smallpox vaccination, 1968. N. Engl. J. Med. 281:1201-1208.
31. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. 1975. Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA. Infection 3:6-14.
32. McCurdy, L. H., B. D. Larkin, J. E. Martin, and B. S. Graham. 2004. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis. 38:1749-1753.
33. McCurdy, L. H., J. A. Rutigliano, T. R. Johnson, M. Chen, and B. S. Graham. 2004. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J. Virol. 78:12471-12479.
34. Meseda, C. A., A. D. Garcia, A. Kumar, A. E. Mayer, J. Manischewitz, L. R. King, H. Golding, M. Merchlinsky, and J. P. Weir. 2005. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339:164-175.
35. Mortimer, P. P. 2003. The new cell culture smallpox vaccine should not be offered to the general population. Rev. Med. Virol. 13:17-20.
36. Oh, S., J. A. Berzofsky, D. S. Burke, T. A. Waldmann, and L. P. Perera. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100:3392-3397.
37. Oh, S., L. P. Perera, D. S. Burke, T. A. Waldmann, and J. A. Berzofsky. 2004. IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc. Natl. Acad. Sci. USA 101:15154-15159.
38. Otero, M., S. A. Calarota, A. Dai, A. S. De Groot, J. D. Boyer, and D. B. Weiner. 2006. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine 24:4461-4470.
39. Perera, L. P., C. K. Goldman, and T. A. Waldmann. 2001. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc. Natl. Acad. Sci. USA 98:5146-5151.
40. Rao, A. R. 1972. Smallpox. Kothari Book Depot, Bombay, India.
41. Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
42. Stickl, H., V. Hochstein-Mintzel, A. Mayr, H. C. Huber, H. Schäfer, and A. Holzner. 1974. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr. 99: 2386-2392. (In German.)
43. Stittelaar, K. J., G. van Amerongen, I. Kondova, T. Kuiken, R. F. van Lavieren, F. H. Pistoor, H. G. Niesters, G. van Doornum, B. A. van der Zeijst, L. Mateo, P. J. Chaplin, and A. D. Osterhaus. 2005. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkey-pox virus. J. Virol. 79:7845-7851.
44. Waldmann, T. A. 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6:595-601.
45. Williamson, J. D., R. W. Reith, L. J. Jeffrey, J. R. Arrand, and M. Mackett. 1990. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J. Gen. Virol. 71:2761-2767.
46. Wyatt, L. S., P. L. Earl, L. A. Eller, and B. Moss. 2004. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. USA 101:4590-4595.